Document results for
12 results · Page 1 of 2
The possibly life-threatening agranulocytosis expresses itself in a general feeling of illness, associated with fever, chills, palpitations, sore throat and difficulty swallowing as well as painful inflammation of the mucous membranes in the mouth, nose and throat area as well as in the anal and genital area. In these cases, sulfasalazine must be discontinued immediately. Sulfasalazine should ...
www.medac.euFor sulfasalazine given as a single 3g oral dose, peak serum levels of sulfasalazine occurred in 3–5 hours, elimination half-life was 5.7 ±0.7 hours, lag time 1.5 hours.
patient-info.co.ukThe observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. In fast acetylators, the mean plasma half-life of SP is 10.4 hours while in slow acetylators, it is 14.8 hours.
www.accessdata.fda.govSevere, life-threatening, systemic hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms DRESS have been reported in patients taking sulfasalazine. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.
dailymed-beta.nlm.nih.govThe observed plasma half-life for intravenous sulfasalazine is 7.6 ± 3.4 hours. The primary route of metabolism of SP is via acetylation to form AcSP. The rate of metabolism of SP to AcSP is dependent upon acetylator phenotype. In fast acetylators, the mean plasma half-life of SP is 10.4 hours while in slow acetylators, it is 14.8 hours.
dailymed.nlm.nih.govFor sulfasalazine given as a single 3g oral dose, peak serum levels of sulfasalazine occurred in 3-5 hours, elimination half-life was 5.7 ±0.7 hours, lag time 1.5 hours.
imedi.co.ukSulfasalazine reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
www.drugs.comSulfasalazine should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Severe, life-threatening, systemic hypersensitivity reactions such as drug rash with eosinophilia and systemic symptoms have been reported in patients taking sulfasalazine.
dailymed.nlm.nih.govSulfasalazine should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Severe, life-threatening, systemic hypersensitivity reactions such as drug rash with eosinophilia and systemic symptoms have been reported in patients taking sulfasalazine.
dailymed.awsprod.nlm.nih.govSevere, life-threatening, systemic hypersensitivity reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking sulfasalazine. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.
labeling.pfizer.com